 A European study followed 330 psoriatic patients starting secucinium of between January 2016 and February 2017 in 11 centres, assessing effectiveness by relative improvement from baseline of the psoriasis area severity index, posi, and absolute posi score modifications throughout 52 weeks of therapy. The study found that naive to biologics patients showed greater probability to achieve posi scores of less than or equal to 1, less than or equal to 2, less than or equal to 3, and less than or equal to 5 at week 12 compared to bio-experienced patients, with this effectiveness confirmed at week 24 and 52. The study suggests that secucinium is effective in treating psoriasis patients throughout a 52 weeks observation period, with higher response in bio-naive patients. This article was authored by Andrea Chiricosi, Ana Pallato, Curtin Comrade, and others.